Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of ADP-A2M4 SPEAR T cells in advanced synovial sarcoma or myxoid/round cell liposarcoma
2019-000589-39Phase 2Active
- Sponsor
- Adaptimmune Therapeutics
- Start
- Jul 2019
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afamitresgene autoleucel in synovial sarcoma (SS) and Myxoid/round cell liposarcoma (MRCLS), sponsored by Adaptimmune Therapeutics. Primary endpoint: Overall Response Rate. Started Jul 2019; status: active.
02
Drugs
afamitresgene autoleucel
03
Conditions
synovial sarcoma (SS)Myxoid/round cell liposarcoma (MRCLS)
Beyond the preview
Go deeper on 2019-000589-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000589-39.